Cargando…
Immune checkpoint inhibitors in cancer /
Get a quick, expert overview of the latest clinical information and guidelines for cancer checkpoint inhibitors and their implications for specific types of cancers. This practical title by Drs. Fumito Ito and Marc Ernstoff synthesizes the most up-to-date research and clinical guidance available on...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
St. Louis, Missouri :
Elsevier,
[2019]
|
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000Ii 4500 | ||
|---|---|---|---|
| 001 | SCIDIR_on1050869819 | ||
| 003 | OCoLC | ||
| 005 | 20231120010313.0 | ||
| 006 | m o d | ||
| 007 | cr cnu---unuuu | ||
| 008 | 180906s2019 moua ob 001 0 eng d | ||
| 040 | |a OPELS |b eng |e rda |e pn |c OPELS |d OCLCF |d DKU |d MERER |d EBLCP |d NLE |d YDX |d N$T |d YDX |d OCLCO |d OTZ |d U3W |d OCLCA |d OCLCQ |d LVT |d OCLCO |d OCLCA |d OCLCQ |d D6H |d OCLCO |d OCLCQ |d OCLCA |d OCLCQ |d S2H |d OCLCO |d VT2 |d OCLCO |d OCLCQ |d OCLCO | ||
| 015 | |a GBB8E4895 |2 bnb | ||
| 016 | 7 | |a 019006937 |2 Uk | |
| 019 | |a 1052508918 |a 1053831111 |a 1229796988 |a 1235835432 | ||
| 020 | |a 9780323549509 |q (electronic book) | ||
| 020 | |a 0323549500 |q (electronic book) | ||
| 020 | |z 9780323549486 |q (print) | ||
| 020 | |z 0323549489 |q (print) | ||
| 035 | |a (OCoLC)1050869819 |z (OCoLC)1052508918 |z (OCoLC)1053831111 |z (OCoLC)1229796988 |z (OCoLC)1235835432 | ||
| 050 | 4 | |a RC268.3 |b .I66 2019 | |
| 060 | 4 | |a QZ 200 | |
| 072 | 7 | |a HEA |x 039000 |2 bisacsh | |
| 072 | 7 | |a MED |x 014000 |2 bisacsh | |
| 072 | 7 | |a MED |x 022000 |2 bisacsh | |
| 072 | 7 | |a MED |x 112000 |2 bisacsh | |
| 072 | 7 | |a MED |x 045000 |2 bisacsh | |
| 082 | 0 | 4 | |a 616.99/4079 |2 23 |
| 245 | 0 | 0 | |a Immune checkpoint inhibitors in cancer / |c Fumito Ito, Marc S. Ernstoff. |
| 264 | 1 | |a St. Louis, Missouri : |b Elsevier, |c [2019] | |
| 300 | |a 1 online resource | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 504 | |a Includes bibliographical references and index. | ||
| 505 | 0 | |a Intro; Title page; Table of Contents; Copyright; Dedication; List of Contributors; Preface; Chapter 1. Immune Checkpoint Inhibitors: Mechanisms and Emerging Therapeutic Opportunities; Introduction; Immune Checkpoint Inhibition: Molecules and Mechanisms; Regulation of the Immune Checkpoint Molecules on Activated T Cells; Regulation of the Expression of Immune Checkpoint Ligands; Factors Affecting the Anti tumor Effectiveness of Immune Checkpoint Inhibitors; Targeting the Tumor Microenvironment to Enhance the Therapeutic Effectiveness of Immune Checkpoint Inhibitors; Conclusions | |
| 505 | 8 | |a Chapter 2. Immune Checkpoints: Melanoma and Other Skin Cancers melanoma; Background; Ipilimumab (Anti-CTLA-4 Antibody); PD-1 Blockade; Special Considerations With the Use of Immune Checkpoint Inhibitor; Duration of Treatment; The Use of Immune Checkpoint Inhibitors in Specific Populations; Immune Checkpoint Inhibitors for Adjuvant Therapy; Biomarkers for Immune Checkpoint Inhibitor Response; Mechanisms of Resistance; Novel Immune Checkpoint Inhibitors and Combinations in Development; Conclusion; Merkel Cell Carcinoma; Immunotherapy of Merkel Cell Carcinoma; Conclusion; Conclusion | |
| 505 | 8 | |a Chapter 3. The Current Status of Immunotherapy in Thoracic Malignancies Introduction; Immune Checkpoint Inhibition; Non-Small-Cell Lung Cancer; Biomarkers of Response or Resistance to Immune Checkpoint Inhibitor Therapy; Future Directions; Combination Therapy With Other Immunotherapy; Non-Small-Cell Lung Cancer; Individualized Tumor Neoantigen-Based Vaccines; Conclusion; Chapter 4. Immune Checkpoint Inhibitors in Gastrointestinal Malignancies; Introduction; Gastroesophageal Cancer; Hepatocellular Carcinoma; Cholangiocarcinoma; Pancreatic Adenocarcinoma; Colorectal Cancer; Anal Cancer | |
| 505 | 8 | |a Patient Selection for Immunotherapy and Biomarker Development summary/Conclusion; Chapter 5. Cancers of the Head and Neck; Introduction; Molecular Biology of Head and Neck Cancers; Immune Escape in Head and Neck Cancer; Squamous Cell Carcinoma of Head and Neck; Nasopharyngeal Carcinoma; Salivary Glands Cancer; Conclusion; Chapter 6. Urologic Malignancies; Kidney Cancer; Background: Prior Immunotherapies in Renal Cell Carcinoma; Single-Agent Immune Checkpoint Inhibitors; Combination or ICI-VEGFi; Bladder Cancer; PD-L1-Targeted Agents; PD-L1-Targeted Agents; CTLA-4-Targeted Agents; Other Agents | |
| 505 | 8 | |a Prostate Cancer Chapter 7. Gynecologic Malignancies; Introduction; Ovarian Cancer; Endometrial Cancer; Cervical Cancer; Future Directions; Chapter 8. Breast Cancer; Introduction; Mutational Burden/Tumor-Associated Antigens in Breast Cancer; Significance of Tumor-Infiltrating Lymphocytes in Breast Cancer; Programmed Death-Ligand 1 [PD-L1] PD-L1 Expression in Breast Cancer; PD-L1 and PD-1 Inhibitor Studies in Metastatic Breast Cancer; Neoadjuvant Breast Studies; Conclusion; Chapter 9. Hematologic Malignancies; Introduction; Immune Checkpoint Pathway Dysregulation in Hematologic Malignancies | |
| 588 | 0 | |a Online resource; title from digital title page (viewed on November 12, 2018). | |
| 520 | |a Get a quick, expert overview of the latest clinical information and guidelines for cancer checkpoint inhibitors and their implications for specific types of cancers. This practical title by Drs. Fumito Ito and Marc Ernstoff synthesizes the most up-to-date research and clinical guidance available on immune checkpoint inhibitors and presents this information in a compact, easy-to-digest resource. It's an ideal concise reference for trainee and practicing medical oncologists, as well as those in research. Key Features: Discusses the current understanding of how to best harness the immune system against different types of cancer at various stages; Helps you translate current research and literature into practical information for daily practice; Presents information logically organized by disease site; Covers tumor immunology and biology, toxicities associated with immune checkpoint inhibitors, and future outlooks; Consolidates today's available information on this timely topic into one convenient resource. | ||
| 650 | 0 | |a Cancer |x Immunological aspects. | |
| 650 | 2 | |a Neoplasms |x immunology |0 (DNLM)D009369Q000276 | |
| 650 | 6 | |a Cancer |x Immunologie. |0 (CaQQLa)201-0004695 | |
| 650 | 7 | |a HEALTH & FITNESS |x Diseases |x General. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Clinical Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Diseases. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Evidence-Based Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Internal Medicine. |2 bisacsh | |
| 650 | 7 | |a Cancer |x Immunological aspects |2 fast |0 (OCoLC)fst00845383 | |
| 700 | 1 | |a Ito, Fumito, |e editor. | |
| 700 | 1 | |a Ernstoff, Marc S., |e editor. | |
| 776 | 0 | 8 | |i Print version: |a Ito, Fumito. |t Immune Checkpoint Inhibitors in Cancer. |d Philadelphia : Elsevier, �2018 |z 9780323549486 |
| 856 | 4 | 0 | |u https://sciencedirect.uam.elogim.com/science/book/9780323549486 |z Texto completo |
| 856 | 4 | 1 | |u https://sciencedirect.uam.elogim.com/science/book/9780323549486 |z Texto completo |